Full-Time

Regulatory Operations Manager

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$147k - $163kAnnually

Mid, Senior

San Bruno, CA, USA

This role is onsite hybrid in our South San Francisco office.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor's degree in life sciences, information technology, or business with 6+ years of experience in pharmaceutical Regulatory Operations or similar discipline
  • Hand-on experience publishing, publishing original applications and maintenance submissions for INDs, NDAs, CTAs, MAAs (EU and other countries), and NDSs.
  • Experience with project managing complex submissions.
  • Proficient knowledge of and experience with electronic publishing tools for regulatory submissions (e.g., Lorenz docuBridge, Extedo eCTD Manager, IQVIA RIM Smart, etc.).
  • Thorough understanding of applicable FDA, HC, EU and ICH guidelines related to regulatory submissions, clinical trials and marketing applications.
  • Expert knowledge of eCTD submission requirements and lifecycle management concepts for eCTD submissions.
  • Expert skills in using MS Office Suite, Adobe Acrobat and ISIToolBox, SharePoint, EndNote, Accenture StartingPoint templates, and other relevant tools.
  • Experience with document formatting (Word and PDF).
  • Demonstrated organizational skills, attention to detail and ability to quickly adjust to changes in priorities and work under pressure in a fast-paced environment to meet tight submission and project deadlines.
  • Strong project management, communication and interpersonal skills; demonstrated ability to independently learn new technologies, processes and regulatory requirements.
  • Ability to work independently, troubleshoot system and validation errors, and make knowledgeable decisions.
Responsibilities
  • Publish high-quality electronic regulatory submissions (eCTD and other formats as appropriate) for submittal to global health authorities including FDA, EMA, Swiss Medic, Health Canada, and others
  • Publish submissions ranging in complexity from routine (e.g., IND investigator updates) to original applications and major updates to existing applications (e.g., original INDs/NDAs/MAAs, sNDAs, major IND amendments)
  • Manage and triage workload for large/complex submissions
  • Format MS word documents and reports, and ensure generation of final PDF documents that conform to health authority technical requirements. In addition, prepare CSR appendices and perform report-level publishing
  • Perform quality control checks on formatted documents and published outputs prior to submission to health authorities
  • Provide training on Cytokinetics CTD/document templates sand style guide
  • Archive paper and electronic submissions
  • Provide Regulatory Affairs and other Cytokinetics functions guidance during document development on aspects related to publishing and electronic submissions
  • Identify and resolve document formatting and/or publishing issues, working with responsible parties as needed
  • Monitor changes to ICH and health authority electronic submission guidance and work with Regulatory Operations team to update processes and standards
  • Assist with development of new and updated department SOPs, Work Instructions

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?